Table 2.
Univariate and multivariate analyses of OS in patients
| Characteristic | Before PSM | After PSM | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||||||
| HR | 95%CI | P | HR | 95%CI | P | HR | 95%CI | P | HR | 95% CI | P | ||
| Age (y) | ≤60/ >60 | 1.408 | 0.565‐3.508 | .462 | NI | 1.155 | 0.455‐2.933 | .761 | NI | ||||
| Gender | Female/ Male | 1.515 | 0.596‐3.851 | .383 | NI | 1.529 | 0.592‐3.951 | .380 | NI | ||||
| Tumor size (cm) | ≤2/2 ~ 4/>4 | 0.927 | 0.394‐2.180 | .861 | NI | 1.109 | 0.458‐2.687 | .818 | NI | ||||
| Tumor grade | Well/ Moderate/ Poor | 2.921 | 1.259‐6.774 | .013 | 2.715 | 1.121‐6.575 | .027 | 2.574 | 1.114‐5.949 | .027 | 2.162 | 0.894‐5.227 | .087 |
| LN metastasis | Absent/ Present | 2.551 | 0.741‐8.787 | .138 | NI | 2.563 | 0.737‐8.916 | .139 | NI | ||||
| Tumor site | Head/ Body/ Tail | 1.151 | 0.629‐2.103 | .649 | NI | 1.170 | 0.608‐2.249 | .638 | NI | ||||
| WBC (*109) | ≤10/ >10 | 1.642 | 0.477‐5.651 | .432 | NI | 1.662 | 0.480‐5.761 | .423 | NI | ||||
| HGB (g/L) | ≤120/ >120 | 0.556 | 0.073‐4.221 | .570 | NI | 0.540 | 0.071‐4.119 | .552 | NI | ||||
| PLT (*109) | ≤300/ >300 | 0.898 | 0.260‐3.105 | .865 | NI | 1.269 | 0.357‐4.512 | .712 | NI | ||||
| ALT (U/L) | ≤40/ >40 | 0.760 | 0.287‐2.016 | .581 | NI | 0.697 | 0.247‐1.966 | .495 | NI | ||||
| AST (U/L) | ≤40/ >40 | 1.466 | 0.484‐4.440 | .499 | NI | 1.059 | 0.305‐3.671 | .929 | NI | ||||
| ALP (U/L) | ≤100/ >100 | 0.900 | 0.361‐2.244 | .822 | NI | 0.864 | 0.334‐2.233 | .763 | NI | ||||
| GGT (U/L) | ≤45/ >45 | 1.205 | 0.488‐2.973 | .686 | NI | 1.218 | 0.482‐3.075 | .676 | NI | ||||
| ALB (g/L) | ≤40/ >40 | 0.167 | 0.060‐0.467 | .001 | 0.189 | 0.062‐0.581 | .004 | 0.200 | 0.068‐0.593 | .004 | 0.240 | 0.074‐0.780 | .018 |
| TBIL (µmol/L) | ≤20.5/ >20.5 | 0.661 | 0.192‐2.270 | .511 | NI | 0.656 | 0.190‐2.268 | .505 | NI | ||||
| IBIL (µmol/L) | ≤15/ >15 | 1.270 | 0.288‐5.598 | .752 | NI | 1.318 | 0.297‐5.853 | .716 | NI | ||||
| CRP (ng/L) | ≤3/ >3 | 2.613 | 1.047‐6.519 | .039 | 1.384 | 0.511‐3.746 | .523 | 3.127 | 1.185‐8.250 | .021 | 1.848 | 0.603‐5.662 | .282 |
| CEA (ng/mL) | ≤5/ >5 | 1.488 | 0.556‐3.979 | .429 | NI | 1.674 | 0.626‐4.476 | .304 | NI | ||||
| CA19‐9 (U/ml) | ≤35/ >35 | 1.967 | 0.643‐6.020 | .236 | NI | 2.103 | 0.684‐6.468 | .195 | NI | ||||
| HBsAg | Negative/ Positive | 0.882 | 0.116‐6.686 | .903 | NI | 0.908 | 0.119‐6.918 | .926 | NI | ||||
| Group | IRE/ RFA | 3.151 | 1.220‐8.140 | .018 | 3.870 | 1.426‐10.503 | .008 | 3.320 | 1.264‐8.718 | .015 | 4.120 | 1.493‐11.371 | .006 |
| Chemotherapy type | FOLFIRINOX/ Gem | 0.812 | 0.508‐1.299 | .385 | NI | 0.729 | 0.445‐1.192 | .208 | NI | ||||
Abbreviations: ALB, albumin; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; CA19‐9, carbohydrate antigen 19‐9; CEA, carcinoembryonic antigen; CRP, C‐reactive protein; GGT, glutamyl transpeptidase; HBsAg, hepatitis B surface antigen; HBsAg, hepatitis B surface antigen; IBIL, indirect bilirubin; LN, lymph node metastasis; PLT, platelet count; TBIL, total bilirubin; TNM, tumor‐node‐metastasis stage; WBC, white blood cell count.